Sabcomeline
From Wikipedia, the free encyclopedia
Jump to: navigation, search
 |
|
| Clinical data | |
|---|---|
| ATC code | None |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | 159912-58-0 |
| PubChem (CID) | 9577995 |
| IUPHAR/BPS | 306 |
| ChemSpider | 7852359 |
| UNII | P8P92V596C  Y |
| ChEMBL | CHEMBL134641 |
| Chemical and physical data | |
| Formula | C10H15N3O |
| Molar mass | 193.12 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
Sabcomeline (Memric; SB-202,026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease.[1] It made it to phase III clinical trials before being discontinued due to poor results.
See also[edit]
References[edit]
- ^ Loudon JM, Bromidge SM, Brown F, et al. (December 1997). "SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors". The Journal of Pharmacology and Experimental Therapeutics. 283 (3): 1059–68. PMID 9399977.
| AChE inhibitors | |
|---|---|
| Others | |
